SHERIDAN, WYOMING – May 9, 2025 – LivaNova PLC, a global leader in medical technology, announced strong first-quarter 2025 results today, demonstrating continued growth and operational efficiency. The company reported high single-digit revenue growth, including double-digit organic revenue increases, as well as expanding operating margins. LivaNova also raised its full-year 2025 revenue guidance, taking into account the impact of the SNIA environmental liability and current tariffs.
Strong Financial Performance in Q1 2025
For the first quarter of 2025, LivaNova recorded total revenue of $316.9 million, a 7.4% increase compared to the same period in 2024. On a constant-currency basis, revenue grew by 8.9%, with organic revenue expanding by 10.4%. Key drivers of growth included strong demand in the Cardiopulmonary and Neuromodulation segments, as well as increased sales from the Essenz™ Perfusion System and cardiopulmonary consumables.
Despite a significant liability from the SNIA case, LivaNova achieved adjusted diluted earnings per share of $0.88, a notable increase from $0.73 in Q1 2024. Net cash provided by operating activities was $24.0 million, and the company generated $20.0 million in adjusted free cash flow.
Expansion and Innovation Across Key Segments
LivaNova’s Cardiopulmonary segment saw substantial growth, with a reported revenue increase of 13.1%, or 15.0% on a constant-currency basis. The Essenz Perfusion System continues to perform strongly, alongside a robust demand for cardiopulmonary consumables.
In the Neuromodulation segment, LivaNova reported a revenue increase of 3.8% on a reported basis and 4.7% on a constant-currency basis, driven by solid performances in Europe and the Rest of World regions. The company’s continued investment in innovation in neurological treatments, such as the development of the aura6000™ System for obstructive sleep apnea, underscores its commitment to improving patient outcomes.
Regulatory and Clinical Milestones
LivaNova also made significant strides in its obstructive sleep apnea program. The company completed its premarket approval (PMA) submission for the aura6000™ System to the U.S. Food and Drug Administration, marking a critical step toward bringing the innovative treatment to market. This is supported by encouraging data from the OSPREY trial, which demonstrated a 65% active patient responder rate at 12 months, alongside substantial reductions in apnea and oxygen desaturation indices.
Updated Full-Year 2025 Guidance
Based on strong performance in Q1, LivaNova has raised its full-year 2025 revenue growth guidance. The company now expects revenue to grow between 6.0% and 7.0% on a constant-currency basis and between 7.0% and 8.0% on an organic basis. This is an upward revision from previous projections. Additionally, adjusted diluted earnings per share for the year is now expected to range from $3.60 to $3.70, reflecting stronger operational performance.
LivaNova’s revised guidance also accounts for the financial impact of the SNIA environmental liability and applicable tariffs, though the company remains optimistic about mitigating these factors through strategic initiatives.
Strategic Focus on Growth and Operational Excellence
Vladimir Makatsaria, CEO of LivaNova, commented on the results, stating, "In the first quarter, LivaNova delivered solid revenue growth, driven by the ongoing success of the Essenz™ rollout, demand for Cardiopulmonary consumables, and strong Neuromodulation performance. These achievements reflect effective execution across the organization and reinforce our focus on talent, innovation, growth, and operational excellence."
Conclusion and Forward-Looking Outlook
As LivaNova continues to drive innovation and achieve key regulatory milestones, its robust financial performance sets a strong foundation for the remainder of 2025. The company’s strategic focus on operational efficiency, coupled with its leading medical technologies, positions it well for continued growth and success in the global healthcare market.
Learn more at LivaNova's official website.